Olaparib: Phase III started

AstraZeneca began the double-blind, placebo-controlled, Phase III SOLO 2 (ENGOT-Ov21) trial to evaluate 300 mg oral olaparib twice daily in about 264 patients with BRCA-mutated, platinum-sensitive, relapsed ovarian cancer who are in complete or partial response following >=2 lines of platinum-based chemotherapy. AstraZeneca is conducting the trial with the European Network of Gynecological Oncological Trial Groups. AstraZeneca will use the BRACAnalysis test from Myriad Genetics Inc. (NASDAQ:MYGN, Salt Lake City, Utah) as a companion diagnostic to select patients likely to respond to olaparib (see BioCentury, June 17). ...